EU grants for medtech companies
Open-call snapshot checked 2026-04-18
Medtech and medical-device companies can access EU funding mainly through Horizon Europe's health cluster (for clinical research and innovation) and the EIC Accelerator (for breakthrough single-company innovation with a route to market).
Best-fit programmes
These are the EU programmes most relevant to medtech companies. Each guide explains eligibility, funding rates, and the calls open now.
Where medtech funding sits
Medical-device innovation is funded across Horizon Europe's health cluster, where collaborative projects can cover clinical validation, evidence generation, and health-system integration. A single company with a breakthrough device and a clear market path is a strong fit for the EIC Accelerator.
EU4Health is less about device development and more about prevention, preparedness, and the deployment of health technology within health systems.
Regulation shapes the timing
For medtech, the regulatory pathway under the EU Medical Device Regulation is part of the funding case. Strong proposals show where the device sits on the route to certification and how grant funding accelerates clinical evidence and market access rather than replacing it.
Reviewers expect realistic timelines: clinical validation and certification take time, and proposals that ignore this lose credibility.
Choosing the right route
Collaborative clinical research and evidence generation point to Horizon Europe. A single company scaling a breakthrough device points to the EIC Accelerator. Deployment within health systems points to EU4Health. Companies developing digital diagnostics should also review the healthtech guidance.
Open calls relevant to medtech companies
These open EU calls in the current index snapshot mention themes relevant to medtech companies. Keyword filtering is a starting point, not an eligibility check — run a free match for a proper fit assessment.
- Horizon Europe109d left
European Partnership on Rare Diseases (ERDERA) (Phase 2)
Review fit, deadline, and source View on the EU Funding & Tenders Portal ↗ - Horizon Europe109d left
Microbiome pour la prédiction précoce du cancer avant l'apparition de la maladie
Review fit, deadline, and source View on the EU Funding & Tenders Portal ↗ - Horizon Europe319d left
Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Review fit, deadline, and source View on the EU Funding & Tenders Portal ↗ - Horizon Europe319d left
Development of innovative antimicrobials against pathogens resistant to antimicrobials
Review fit, deadline, and source View on the EU Funding & Tenders Portal ↗ - Horizon Europe319d left
Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Review fit, deadline, and source View on the EU Funding & Tenders Portal ↗ - Horizon Europe319d left
Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Review fit, deadline, and source View on the EU Funding & Tenders Portal ↗ - Horizon Europe319d left
Clinical trials for advancing innovative interventions for neurodegenerative diseases
Review fit, deadline, and source View on the EU Funding & Tenders Portal ↗ - Horizon Europe319d left
Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Review fit, deadline, and source View on the EU Funding & Tenders Portal ↗
Frequently asked questions
Can a medical device company get EU grants?
Yes. Medical-device companies are eligible for Horizon Europe health-cluster calls and the EIC Accelerator. The right route depends on whether the work is collaborative clinical research or single-company scale-up.
Does EU funding cover clinical validation?
Clinical validation can be funded within Horizon Europe health projects when it is part of a research and innovation action. The call topic defines which clinical activities are in scope and to what extent.
How does device regulation affect a grant application?
A credible medtech proposal places the device on its regulatory pathway under the EU Medical Device Regulation and shows how the grant accelerates clinical evidence and certification. Ignoring the regulatory timeline weakens the proposal.